|
US 11,952,352 B2 |
|
| Ras inhibitors |
| Adrian L. Gill, Atherton, CA (US); James Cregg, Belmont, CA (US); Elena S. Koltun, Foster City, CA (US); and Yang Liu, Foster City, CA (US) |
| Assigned to Revolution Medicines, Inc., Redwood City, CA (US) |
| Filed by Revolution Medicines, Inc., Redwood City, CA (US) |
| Filed on Jan. 30, 2023, as Appl. No. 18/161,266. |
| Application 18/161,266 is a continuation of application No. 17/089,035, filed on Nov. 4, 2020, granted, now 11,566,007, issued on Jan. 31, 2023. |
| Claims priority of provisional application 63/043,588, filed on Jun. 24, 2020. |
| Claims priority of provisional application 63/011,636, filed on Apr. 17, 2020. |
| Claims priority of provisional application 63/000,357, filed on Mar. 26, 2020. |
| Claims priority of provisional application 62/951,652, filed on Dec. 20, 2019. |
| Claims priority of provisional application 62/930,355, filed on Nov. 4, 2019. |
| Prior Publication US 2023/0234929 A1, Jul. 27, 2023 |
| Int. Cl. C07D 487/08 (2006.01); A61K 31/504 (2006.01); A61P 35/00 (2006.01); C07D 245/04 (2006.01) |
